Levodopa - Generic Drug Details

What are the generic drug sources for levodopa and what is the scope of patent protection?

Levodopa is the generic ingredient in four branded drugs marketed by Valeant Pharm Intl, Shire, Roche, and Merz, and is included in four NDAs. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Levodopa has ninety-eight patent family members in twenty-two countries.

There are eighteen drug master file entries for levodopa. One supplier is listed for this compound.

Summary for levodopa

International Patents:	98
US Patents:	5
Tradenames:	4
Applicants:	4
NDAs:	4
Drug Master File Entries:	18
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	134
Clinical Trials:	471
What excipients (inactive ingredients) are in levodopa?	levodopa excipients list
DailyMed Link:	levodopa at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for levodopa

Dosage:

POWDER;INHALATION

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for levodopa

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Prothena Biosciences Limited	PHASE3
Hoffmann-La Roche	PHASE3
University Hospital Tuebingen	PHASE3

See all levodopa clinical trials

Pharmacology for levodopa

Drug Class

Aromatic Amino Acid

Medical Subject Heading (MeSH) Categories for levodopa

Antiparkinson Agents

Dopamine Agents

Anatomical Therapeutic Chemical (ATC) Classes for levodopa

N04BA	Dopa and dopa derivatives
N04B	DOPAMINERGIC AGENTS
N04	ANTI-PARKINSON DRUGS
N	Nervous system

US Patents and Regulatory Information for levodopa

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Shire	DOPAR	levodopa	CAPSULE;ORAL	016913-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Valeant Pharm Intl	BENDOPA	levodopa	CAPSULE;ORAL	016948-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Roche	LARODOPA	levodopa	CAPSULE;ORAL	016912-006	Approved Prior to Jan 1, 1982		DISCN	No	No
Valeant Pharm Intl	BENDOPA	levodopa	CAPSULE;ORAL	016948-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018		RX	Yes	Yes			Y

Expired US Patents for levodopa

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018
Merz	INBRIJA	levodopa	POWDER;INHALATION	209184-001	Dec 21, 2018

EU/EMA Drug Approvals for levodopa

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Acorda Therapeutics Ireland Limited	Inbrija	levodopa	EMEA/H/C/004786Inbrija is indicated for the intermittent treatment of episodic motor fluctuations (OFF episodes) in adult patients with Parkinson’s disease (PD) treated with a levodopa/dopa-decarboxylase inhibitor.	Authorised	no	no	no	2019-09-19

International Patents for levodopa

Country	Patent Number	Title	Estimated Expiration
Japan	2015536988	肺使用のための高服用量のレボドパを含むカプセル
World Intellectual Property Organization (WIPO)	2014074795
Hungary	E031167
Hong Kong	1213186	用於肺部使用的高劑量左旋多巴膠囊 (HIGH DOSE LEVODOPA CAPSULES FOR PULMONARY USE)
South Korea	20210152020	폐용 초저밀도 분말 (ULTRA LOW DENSITY PULMONARY POWDERS)

Supplementary Protection Certificates for levodopa

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3209302	LUC00304	Luxembourg		PRODUCT NAME: COMBINAISON DE FOSLEVODOPA ET DE FOSCARBIDOPA, CHACUNE SOUS TOUTES SES FORMES PROTEGEES PAR LE BREVET DE BASE; MARKETING AUTHORISATION NUMBER AND DATE: 141371, 20220826
1613296	CR 2015 00042	Denmark		PRODUCT NAME: KOMBINATION AF SAFINAMID, HERUNDER SAFINAMID METHANSULFONAT, OG LEVODOPA/PDI; REG. NO/DATE: EU/1/14/984/001-010 20150226
3209302	CR 2023 00015	Denmark		PRODUCT NAME: KOMBINATION AF FOSLEVODOPA ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF OG FOSCARBIDOPA ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; NAT. REG. NO/DATE: 66549 (DK) 20221205; FIRST REG. NO/DATE: AT 141371 20220826
3209302	2023C/510	Belgium		PRODUCT NAME: COMBINATIE VAN FOSLEVODOPA EN FOSCARBIDOPA, ELK IN ALLE VORMEN BESCHERMD DOOR HET BASISOCTROOI; AUTHORISATION NUMBER AND DATE: BE660571 20220901
3209302	23C1035	France		PRODUCT NAME: COMBINAISON DE FOSLEVODOPA ET DE FOSCARBIDOPA, CHACUNE DANS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE; NAT. REGISTRATION NO/DATE: 34009 302 790 8 3 20230901; FIRST REGISTRATION: AT - 141371 20220826

Market Dynamics and Financial Trajectory for Levodopa

Last updated: July 28, 2025

Introduction

Levodopa, also known as L-DOPA, remains the gold standard for Parkinson’s disease (PD) management since its approval in the 1960s. As a dopamine precursor, levodopa effectively alleviates motor symptoms, cementing its position as the cornerstone of PD therapy. This analysis evaluates the prevailing market dynamics and projects the financial trajectory of levodopa, considering recent innovations, regulatory shifts, and the evolving landscape of neurodegenerative disease treatment.

---

Market Overview

Global Sales and Market Size

Levodopa continues to generate substantial revenue, with estimates valuing the global Parkinson’s disease drug market at approximately $4.2 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of about 7% over the next five years [1]. Levodopa accounts for around 60-70% of this market share, reflective of its central role in symptomatic management.

Key Market Players

Major pharmaceutical companies, including AbbVie, Teva Pharmaceuticals, and Sun Pharmaceutical Industries, dominate levodopa production and distribution. These entities leverage established formulations like Sinemet (carbidopa/levodopa) and Madopar (benserazide/levodopa), which maintain steady demand despite the advent of novel treatment modalities.

Prevalence Drivers

The rising global prevalence of Parkinson’s disease, driven by aging populations, fuels ongoing demand. The World Health Organization estimates over 10 million people worldwide suffer from PD, with cases expected to double by 2040 [2].

---

Market Dynamics

Innovation and Formulation Advances

While traditional levodopa formulations have a longstanding market presence, ongoing innovation aims to improve pharmacokinetic profiles and reduce side effects. Extended-release formulations (e.g., Rytary) and novel delivery systems such as intestinal gel infusion are gaining traction. These adaptations aim to mitigate motor fluctuations, a common complication in long-term levodopa therapy.

Emerging Therapies and Competitive Pressure

The development of dopamine agonists, MAO-B inhibitors, and gene therapies pose competitive challenges. Notably, drugs like safinamide and rotigotine provide alternative symptomatic relief, although levodopa remains the most potent for motor symptom control. However, the concurrent risk of dyskinesia and motor fluctuation in levodopa users encourages investment into adjunctive therapies and new delivery methods.

Regulatory and Patent Landscape

Levodopa formulations face a patent expiry cycle, with generic versions expanding accessibility and exerting downward pressure on prices. Regulatory bodies continue to approve new formulations with improved delivery mechanisms, impacting market shares.

Impact of Biomarker and Diagnostic Advances

Earlier diagnosis of PD, aided by advances in biomarker research, enhances the potential market size, as patients can start levodopa therapy sooner. Early intervention strategies may modify disease progression and potentially extend the duration of levodopa therapy’s dominance.

Market Challenges

• Side Effect Profile: Long-term use can lead to dyskinesia, wearing-off phenomena, and fluctuations, which restrict optimal dosing.
• Development of Disease-Modifying Drugs: Current efforts to discover therapies that slow PD progression may eventually reduce reliance on symptomatic drugs like levodopa.

---

Financial Trajectory Forecast

Forecast Assumptions

• Steady increase in PD prevalence due to demographic shifts.
• Incremental improvements in formulations prolonging drug efficacy.
• Adoption of combination therapies and innovative delivery systems.
• Continued patent expiries leading to generic penetration.
• Emerging disease-modifying treatments emerging over the next decade.

Projected Revenue Trends

Based on current market data and growth projections, levodopa's global sales are expected to witness a CAGR of approximately 6-7% through 2030 [1], reaching an estimated $7 billion in annual revenue. The expansion is driven primarily by rising patient numbers and improved formulations that command higher prices.

Impact of Generics and Pricing Dynamics

Patent expirations are expected to lead to significant price reductions in established levodopa formulations, potentially offsetting volume-driven growth. However, new formulations with advanced delivery mechanisms may command premium prices, sustaining revenue levels.

Potential Disruptors

The introduction of disease-modifying therapies or neuroprotective agents could alter the levodopa market landscape, potentially reducing reliance on symptomatic management over the long term. Additionally, biotechnological advances may lead to novel delivery platforms or alternative treatments, influencing levodopa’s market share.

---

Strategic Implications

• For Manufacturers: Invest in formulation innovations that prolong levodopa’s efficacy and reduce side effects to maintain competitiveness.
• For Investors: Monitor developments in disease-modifying PD therapies, as these could impact levodopa’s long-term market relevance.
• For Healthcare Systems: Consider increasing adoption of generics and cost-effective formulations to optimize resource allocation.

---

Key Market Opportunities

1. Extended-Release and Multiparticulate Formulations: To improve patient compliance and reduce fluctuations.
2. Novel Delivery Systems: Such as sustained-release transdermal patches or implantable pumps.
3. Combination Therapies: Potential to enhance efficacy, reduce side effects, and extend levodopa’s therapeutic window.
4. Biomarker-Based Early Diagnosis: Facilitates earlier intervention, expanding the treatment window.

---

Conclusion

Levodopa remains central to Parkinson’s disease treatment, supported by a growing and aging global population. Despite challenges from generics and emerging therapies, innovation in formulations and delivery methods, along with demographic trends, support a robust financial trajectory. The drug’s market landscape is poised for modest growth, shaped by technological advances and regulatory shifts, with potential long-term adjustments stemming from developments in disease-modifying treatments.

---

Key Takeaways

• Levodopa continues to dominate the PD drug market, with projected revenues reaching approximately $7 billion by 2030.
• Market growth is driven by increasing PD prevalence, formulation innovations, and improved patient management strategies.
• Patent expiries and generic entries exert downward pressure on prices but are counterbalanced by demand for advanced formulations.
• Ongoing research into delivery systems and combination therapies offers avenues to extend levodopa’s market lifecycle.
• Emerging disease-modifying drugs may eventually redefine PD management, impacting levodopa’s long-term market share.

---

FAQs

1. How will patent expirations impact levodopa’s market in the coming years?
Patent expirations will lead to increased generic competition, driving down prices and potentially reducing revenue for branded formulations. However, new formulations with innovative delivery systems are expected to sustain premium pricing, balancing the market dynamics.

2. Are there any new formulations of levodopa currently in development?
Yes. Several extended-release and intestinal gel formulations are in advanced stages of development, aimed at reducing motor fluctuations and enhancing patient adherence.

3. How might emerging disease-modifying therapies affect levodopa’s market share?
Disease-modifying therapies could delay the progression of PD, potentially reducing reliance on symptomatic treatments like levodopa. However, given the current lack of approved neuroprotective drugs, levodopa will likely retain its central role in the near term.

4. What are the main challenges faced by levodopa formulations today?
Management of motor fluctuations, dyskinesia, and the development of long-acting formulations are critical challenges. Additionally, balancing cost with therapeutic efficacy remains a concern.

5. Considering demographic trends, what is the long-term outlook for levodopa?
The long-term outlook remains optimistic, driven by increasing PD prevalence and ongoing innovations in formulation and delivery. Nonetheless, the landscape may evolve with breakthroughs in regenerative medicine and neuroprotection that could supplement or replace current symptomatic therapies.

---

References

[1] MarketWatch. “Global Parkinson’s Disease Drugs Market Size & Trends Report,” 2022.
[2] WHO. “Neurodegenerative Diseases: Parkinson’s Disease,” 2021.